Online Data Supplement. Blood eosinophils and exacerbations in COPD: the Copenhagen General Population. Study
|
|
- Patience Hart
- 7 years ago
- Views:
Transcription
1 Online Data Supplement and exacerbations in COPD: the Copenhagen General Population Study Signe Vedel-Krogh, MD, Sune F. Nielsen, PhD, Peter Lange, DMSc, Jørgen Vestbo, DMSc, and Børge G. Nordestgaard, DMSc
2 Methods All participants completed a questionnaire, underwent a physical examination, and provided blood samples. The study was conducted according to the declaration of Helsinki and approved by the Regional ethics committee (H-KF /01). Spirometry FEV 1 and FVC were determined without the use of a bronchodilator. For the first 14,624 participants of the Copenhagen General Population Study a dry wedge spirometer (Vitalograph; Maids Morton) was used, and for the remaining participants an EasyOne spirometer (nnd Medizintechnik) was used. We derived at the LLN for men and women separately for each spirometer, in a subsample of healthy, asymptomatic, never-smokers using linear regression with age and height as covariates. Individuals were considered asymptomatic if they did not report any respiratory symptoms. FEV 1 as % of the predicted value was calculated separately for each spirometer and seperately for men and women using internally derived references based on the same subsample of healthy, asymptomatic, never-smokers without self-reported asthma in a linear regression with age and height as covariates. Eosinophils White blood cell counts were measured on fresh samples using the ADVIA TM 120 Hematology system subjected to daily precision testing using internal quality control material and monthly accuracy testing using an external control quality program. Eosinophil counts were reported in total numbers ( 10 9 cells/l) together with other leukocyte sub-populations and % of total white blood cell count was calculated. Covariates E2
3 Potential confounders were included in the analyses. Smoking habits were self-reported and participants were grouped as never, former, or current smokers according to the questions Do you smoke? and Have you previously smoked?. Participants also reported on cumulative tobacco consumption and the covariate was defined as tobacco consumed through smoking and measured in terms of pack-years based on the duration of smoking and the amount consumed; 1 pack-year was 20 cigarettes or equivalent smoked daily for one year. Measured weight (kg) and height (m) were used to calculate body mass index (kg/m 2 ). Level of education was dichotomised as low level of education if the participants had none or less than less than three years of education following the Danish mandatory primary school. Weekly alcohol consumption was reported in units where 1 unit 12 grams. A history of hospitalization for ischemic heart disease (World Health Organization International Classification of Diseases: ICD ; ICD10 I20-I25), ischemic cerebrovascular disease (World Health Organization International Classification of Diseases ICD ; ICD10 I61-I69, G45), and diabetes mellitus type 2 (World Health Organization International Classification of Diseases ICD8 250; ICD10 E11) was collected using the national Danish Patient Registry. Imputation of missing characteristics was done by multivariable normal regression. Information on age, sex, height, FVC, FEV 1, and FEV 1 in % of predicted was 100% complete, whereas information on other characteristics were > 98% complete. E3
4 Figure E1. Histogram of blood eosinophils in total number ( 10 9 cells/l) and percentage of leukocytes. E4
5 Figure E2. Histogram of blood eosinophil distributions in the Copenhagen General Population Study. E5
6 Figure E3. ROC curves of levels of blood eosinophils as a marker of mean annual severe exacerbation risk of 0.5 or more and 2 or more. E6
7 Figure E4. Risk of exacerbations according to blood eosinophils and other risk factors. N is the number of individuals, events is the total number of count events. IRR is incidence rate ratio given with 95% confidence interval. All models were multivariable adjusted for age, sex, body mass index and education. All models, except when stratifying according to current smoking status, are adjusted for smoking status. All models, except when stratifying by pack-years, are adjusted for cumulative smoking. All models are adjusted for FEV 1 % of predicted except when stratifying by GOLD stages. All models except when stratifying by blood eosinophil level equal to or above cells/l are adjusted for level of blood eosinophils. E7
8 Figure E5. Risk of severe and moderate exacerbations in individuals with COPD excluding individuals with clinical COPD using the cut-points for blood eosinophils of cells/l and 3.3%. N is the number of individuals, events is the total number of count events. IRR is incidence rate ratio given with 95% confidence interval. Models were multivariable adjusted for age, sex, FEV 1 in % of predicted, smoking status, cumulative smoking, education, and body mass index. E8
9 Figure E6. Mean annual exacerbation rate in the clinical COPD population according to the use of corticosteroids in the year prior to baseline. E9
10 Figure E7. Risk of severe and moderate exacerbations in individuals with COPD and clinical COPD using the cut-points of cells/l, cells/l, 3%, and 4% for blood eosinophils. Incidence rate ratios (IRR) are given with 95% confidence intervals. All models were multivariable adjusted for age, sex, smoking status, cumulative smoking, FEV 1 % of predicted, body mass index, and education. The models marked with * are the models from the main analyses. E10
11 Table E1. Number of participants using inhaled medication at baseline and corresponding Anatomic Therapeutic Chemical codes in the entire COPD population. Medication COPD Clinical COPD (n=7,225) (n=203) Corresponding ATC codes Short-acting β2- R03AC02, R03AC03, R03CC02, 369 (5%) 71 (35%) agonists R03CC03 Long- acting β2- R03AC12, R03AC13, R03AC18, 117 (2%) 15 (7%) agonists R03CC12 Short-acting anticholinergics 21 (0.3%) 7 (3%) R03BB01 Long-acting anticholinergics 235 (3%) 54 (27%) R03BB04 Inhaled corticosteroids 182 (2%) 27 (13%) R03BA01, R03BA02, R03BA05, R03BA07 Combination products 382 (5%) 93 (46%) R03AK03, R03AK04, R03AK06, R03AK07 Number of participants (percentage of all participants) with use of inhalation medication in the year prior to examination. Some participants are using more than one type of medication and therefore the total number is larger than any medication in Table 1. Corresponding codes are Anatomic Therapeutic Chemical codes used in the Danish Registry of Medicinal Products Statistics. E11
12 Table E2. Baseline characteristics of the chronic obstructive pulmonary disease (COPD) and clinical COPD population with a cut-point for total number of blood eosinophils of cells/l. COPD (n=7,225) Clinical COPD (n=203) < cells/l (n=6,205) Blood eosinophils cells/l (n=1,020) P-value < cells/l (n=165) cells/l (n=38) P-value Men (%) 2,984 (48%) 626 (61%) (46%) 33 (87%) Age (years) 63 (54-72) 65 (56-74) (64-77) 72 (66-78) 0.69 (10 9 cells/l) 0.16 ( ) 0.42 ( ) ( ) 0.43( ) (%) 2.2 ( ) 5.2 ( ) ( ) 5.2 ( ) FEV 1 (%) of predicted 79 (65-90) 76 (61-88) (40-61) 48 (43-56) 0.32 FEV 1/FVC 63 (59-66) 63 (58-66) (48-61) 53 (48-61) 0.80 Body-mass index, kg/m ( ) 25.3 ( ) ( ) 25.3 ( ) 0.95 Current smokers (%) 2,282 (37%) 421 (41%) (40%) 10 (26%) 0.12 Pack-years 29 (15-44) 32 (20-48) (26-50) 45 (39-63) 0.11 Familial disposition to asthma (%) 1,935 (31%) 333 (33%) (41%) 16 (42%) 0.87 Asthma, hay fever, or eczema during childhood (%) 623 (10%) 115 (11%) (4%) 4 (11%) 0.08 Allergy (%) 1,218 (20%) 231 (23%) (16%) 6 (16%) 0.93 Low level of education (%) 3,341 (54%) 564 (55%) (70%) 28 (74%) 0.63 Occupational exposure to dust or fumes (%) 962 (16%) 195 (19%) (30%) 12 (32%) 0.82 History of respiratory infections (%) 1,930 (31%) 338 (33%) (68%) 29 (76%) 0.33 Wheezing during a cold (%) 1,030 (17%) 237 (23%) (35%) 18 (47%) 0.14 mmrc 2 (%) 1,042 (17%) 198 (19%) (57%) 26 (68%) 0.20 Sputum for 3 months 1,085 (17%) 250 (25%) (41%) 21 (55%) 0.10 Weekly alcohol consumption (units) 9 (4-17) 10 (4-18) (3-20) 12 (4-21) 0.78 Degree of air flow limitation FEV1 (%) of predicted 80 (%) 2,917 (47%) 427 (42%) FEV1 (%) of predicted <80 (%) 2,761 (45%) 471 (46%) 84 (51%) 16 (42%) FEV1 (%) of predicted <50 (%) 527 (8%) 122 (12%) 81 (49%) 22 (58%) Any inhalation medication 648 (10%) 153 (15%) (61%) 27 (71%) 0.26 Corticosteroids inhalation medication 400 (6%) 94 (9%) (45%) 20 (53%) 0.42 Co-morbidities Ischemic heart disease 499 (8%) 148 (15%) (20%) 11 (29%) 0.23 Ischemic cerebrovascular disease 230 (4%) 52 (5%) (9%) 3 (8%) 0.82 Diabetes mellitus type (2%) 30 (3%) (5%) 3 (8%) 0.57 Hypertension 1,641 (27%) 242 (24%) (27%) 9 (24%) 0.71 Data are n (%) for categorical values and median (interquartile range) for continuous values. COPD = chronic obstructive pulmonary disease. FEV 1 = Forced expiratory volume in 1 second. FVC = Forced vital capacity. mmrc = modified Medical Research Council dyspnea scale. Baseline characteristics were at the date of examination except for inhalation medication which was up to 1 year prior to baseline. Pack-years were calculated for only former and current smokers. Familial disposition to asthma were the reporting of a mother and/or father with asthma. Low education was none or less than 3 years of education following the mandatory primary school. One alcohol unit 12 grams of alcohol. Co-morbidities are hospitalization with a diagnosis of ischemic heart disease, ischemic cerebrovascular disease, or diabetes mellitus type 2 prior to baseline. Hypertension was defined as systolic blood pressure 140 mmhg and diastolic blood pressure 90 mmhg at baseline. P-values are calculated using Wilcoxon s rank-sum test, Pearson's chi-squared tests, or Kruskal Wallis test. E12
13 Table E3. Baseline characteristics of the chronic obstructive pulmonary disease (COPD) and clinical COPD population with a cut-point for blood eosinophils of 3.3%. COPD (n=7,225) Clinical COPD (n=203) <3.3% (n=5,231) Blood eosinophils 3.3% (n=1,994) P-value <3.3% (n=142) 3.3% (n=61) P-value Men (%) 2,416 (46%) 1194 (60%) (46%) 44 (72%) Age (years) 64 (54-72) 65 (55-74) (63-76) 72 (66-78) 0.25 (10 9 cells/l) 0.14 ( ) 0.33 ( ) ( ) 0.37 ( ) (%) 1.9 ( ) 4.4 ( ) ( ) 4.6 ( ) FEV 1 (%) of predicted 79 (65-90) 78 (63-89) (41-61) 48 (40-57) 0.09 FEV 1/FVC 63 (59-66) 63 (58-66) (48-61) 54 (49-60) 0.66 Body-mass index, kg/m ( ) 25.3 ( ) ( ) 25.2 ( ) 0.84 Current smokers (%) 2,023 (39%) 680 (34%) (44%) 14 (23%) Pack-years 30 (15-44) 30 (16-45) (26-50) 40 (30-58) 0.30 Familial disposition to asthma (%) 1,607 (31%) 661 (33%) (40%) 27 (44%) 0.52 Asthma, hay fever, or eczema during childhood (%) 480 (9%) 258 (13%) (3%) 6 (10%) 0.03 Allergy (%) 992 (19%) 457 (23%) (20%) 19 (14%) 0.26 Low level of education (%) 2,814 (54%) 1,091 (55%) (70%) 44 (72%) 0.73 Occupational exposure to dust or fumes (%) 807 (15%) 350 (18%) (28%) 22 (36%) 0.22 History of respiratory infections (%) 1,645 (32%) 623 (31%) (65%) 49 (80%) 0.03 Wheezing during a cold (%) 885 (17%) 382 (19%) (37%) 22 (36%) 0.86 mmrc 2 (%) 887 (17%) 353 (18%) (55%) 42 (69%) 0.06 Sputum for 3 months 933 (18%) 402 (20%) (42%) 28 (48%) 0.43 Weekly alcohol consumption (units) 8 (4-17) 10 (4-18) (4-20) 12 (3-20) 0.58 Degree of air flow limitation FEV 1 (%) of predicted 80 (%) 2,453 (47%) 819 (45%) FEV 1 (%) of predicted <80 (%) 2,329 (45%) 903 (45%) 75 (53%) 25 (41%) FEV 1 (%) of predicted <50 (%) 449 (8%) 200 (10%) 67 (47%) 36 (59%) Any inhalation medication 541 (10%) 260 (13%) (61%) 42 (69%) 0.26 Corticosteroids inhalation medication 333 (6%) 161 (8%) (46%) 30 (49%) 0.66 Co-morbidities Ischemic heart disease 349(8%) 253 (12%) (20%) 16 (26%) 0.30 Ischemic cerebrovascular disease 187 (4%) 95 (5%) (11%) 3 (5%) 0.20 Diabetes mellitus type (2%) 49 (2%) (6%) 3 (5%) 0.69 Hypertension 1,361 (26%) 522 (26%) (27%) 15 (25%) 0.75 Data are n (%) for categorical values and median (interquartile range) for continuous values. COPD = chronic obstructive pulmonary disease. FEV 1 = Forced expiratory volume in 1 second. FVC = Forced vital capacity. mmrc = modified Medical Research Council dyspnea scale. Baseline characteristics were at the date of examination except for inhalation medication which was up to 1 year prior to baseline. Pack-years were calculated for only former and current smokers. Familial disposition to asthma were the reporting of a mother and/or father with asthma. Low education was none or less than 3 years of education following the mandatory primary school. One alcohol unit 12 grams of alcohol. Co-morbidities are hospitalization with a diagnosis of ischemic heart disease, ischemic cerebrovascular disease, or diabetes mellitus type 2 prior to baseline. Hypertension was defined as systolic blood pressure 140 mmhg and diastolic blood pressure 90 mmhg at baseline. P-values are calculated using Wilcoxon s rank-sum test, Pearson's chi-squared tests, or Kruskal Wallis test. E13
14 Table E4. Baseline characteristics of the chronic obstructive pulmonary disease (COPD) and clinical COPD population with a cut-point for blood eosinophils of 2%. COPD (n=7,225) Clinical COPD (n=203) <2% (n=2,618) Blood eosinophils 2% (n=4,607) P-value <2% (n=69) 2% (n=134) P-value Men (%) 1,124 (43%) 2,486 (54%) (36%) 84 (64%) Age (years) 64 (54-72) 64 (54-73) (63-77) 71 (65-76) 0.40 (10 9 cells/l) 0.10 ( ) 0.24 ( ) ( ) 0.26 ( ) (%) 1.4 ( ) 3.1 ( ) ( ) 3.3 ( ) FEV 1 (%) of predicted 79 (65-90) 78 (64-89) (40-62) 50 (41-60) 0.51 FEV 1/FVC 63 (59-66) 63 (59-66) (47-62) 55 (49-61) 0.60 Body-mass index, kg/m ( ) 25.2 ( ) ( ) 26.0 ( ) 0.13 Current smokers (%) 1,042 (40%) 1,661 (36%) (46%) 44 (33%) 0.06 Pack-years 30 (15-44) 30 (15-45) (24-50) 40 (28-55) 0.56 Familial disposition to asthma (%) 798 (30%) 1,470 (32%) (39%) 56 (42%) 0.71 Asthma, hay fever, or eczema during childhood (%) 220 (8%) 518 (11%) (4%) 7 (5%) 0.78 Allergy (%) 457 (17%) 922 (22%) (20%) 19 (14%) 0.26 Low level of education (%) 1,437 (55%) 2,468 (54%) (81%) 87 (65%) 0.02 Occupational exposure to dust or fumes (%) 388 (15%) 769 (17%) (29%) 41 (31%) 0.81 History of respiratory infections (%) 826 (32%) 1,442 (31%) (67%) 95 (71%) 0.48 Wheezing during a cold (%) 438 (17%) 829 (18%) (38%) 49 (37%) 0.88 mmrc 2 (%) 439 (17%) 801 (17%) (54%) 83 (62%) 0.25 Sputum for 3 months 469 (18%) 866 (19%) (51%) 53 (40%) 0.13 Weekly alcohol consumption (units) 9 (4-17) 10 (4-18) (4-20) 10 (3-20) 0.58 Degree of air flow limitation FEV 1 (%) of predicted 80 (%) 1,222 (47%) 2,122 (46%) FEV 1 (%) of predicted <80 (%) 1,170 (45%) 2,062 (45%) 34 (49%) 66 (49%) FEV 1 (%) of predicted <50 (%) 226 (8%) 423 (9%) 35 (51%) 68 (51%) Any inhalation medication 262 (10%) 539 (12%) (57%) 89 (66%) 0.17 Corticosteroids inhalation medication 158 (6%) 336 (7%) (45%) 67 (50%) 0.20 Co-morbidities Ischemic heart disease 185 (7%) 462 (10%) (17%) 32 (24%) 0.29 Ischemic cerebrovascular disease 95 (4%) 187 (4%) (10%) 11 (8%) 0.65 Diabetes mellitus type 2 67 (3%) 92 (2%) (4%) 9 (8%) 0.50 Hypertension 671 (26%) 1,212 (26%) (20%) 39 (29%) 0.18 Data are n (%) for categorical values and median (interquartile range) for continuous values. COPD = chronic obstructive pulmonary disease. FEV 1 = Forced expiratory volume in 1 second. FVC = Forced vital capacity. mmrc = modified Medical Research Council dyspnea scale. Baseline characteristics were at the date of examination except for inhalation medication which was up to 1 year prior to baseline. Pack-years were calculated for only former and current smokers. Familial disposition to asthma were the reporting of a mother and/or father with asthma. Low education was none or less than 3 years of education following the mandatory primary school. One alcohol unit 12 grams of alcohol. Co-morbidities are hospitalization with a diagnosis of ischemic heart disease, ischemic cerebrovascular disease, or diabetes mellitus type 2 prior to baseline. Hypertension was defined as systolic blood pressure 140 mmhg and diastolic blood pressure 90 mmhg at baseline. P-values are calculated using Wilcoxon s rank-sum test, Pearson's chi-squared tests, or Kruskal Wallis test. E14
Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am
Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation
More informationSponsor Novartis Pharmaceuticals
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study
More informationCOPD and Asthma Differential Diagnosis
COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive
More informationUnderstanding COPD. Carolinas Healthcare System
Understanding COPD Carolinas Healthcare System 2013 This self-directed learning module contains information about the pathophysiology, diagnosis, and treatment of COPD. Target Audience: All RNs and LPNs
More informationInterpretation of Pulmonary Function Tests
Interpretation of Pulmonary Function Tests Dr. Sally Osborne Cellular & Physiological Sciences University of British Columbia Room 3602, D.H Copp building 604 822-3421 sally.osborne@ubc.ca www.sallyosborne.com
More informationwritten by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org/copd
written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org/copd What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are two major diseases included in
More informationPRACTICE PROBLEMS FOR BIOSTATISTICS
PRACTICE PROBLEMS FOR BIOSTATISTICS BIOSTATISTICS DESCRIBING DATA, THE NORMAL DISTRIBUTION 1. The duration of time from first exposure to HIV infection to AIDS diagnosis is called the incubation period.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationCOPD It Can Take Your Breath Away www.patientedu.org
written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are 2 major diseases included in COPD:
More informationHormones and cardiovascular disease, what the Danish Nurse Cohort learned us
Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us Ellen Løkkegaard, Clinical Associate Professor, Ph.d. Dept. Obstetrics and Gynecology. Hillerød Hospital, University of Copenhagen
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationChronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) is the name for a group of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways
More informationThe American Cancer Society Cancer Prevention Study I: 12-Year Followup
Chapter 3 The American Cancer Society Cancer Prevention Study I: 12-Year Followup of 1 Million Men and Women David M. Burns, Thomas G. Shanks, Won Choi, Michael J. Thun, Clark W. Heath, Jr., and Lawrence
More informationMarilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
More informationClinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms
Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,
More informationClinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms
Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,
More informationPulmonary Rehabilitation in Newark and Sherwood
Pulmonary Rehabilitation in Newark and Sherwood With exception of smoking cessation pulmonary rehabilitation is the single most effective intervention for any patient with COPD. A Cochrane review published
More informationSmoking in the United States Workforce
P F I Z E R F A C T S Smoking in the United States Workforce Findings from the National Health and Nutrition Examination Survey (NHANES) 1999-2002, the National Health Interview Survey (NHIS) 2006, and
More informationTests. Pulmonary Functions
Pulmonary Functions Tests Static lung functions volumes Dynamic lung functions volume and velocity Dynamic Tests Velocity dependent on Airway resistance Resistance of lung tissue to change in shape Dynamic
More informationSPIROMETRY FOR HEALTH CARE PROVIDERS Global Initiative for Chronic Obstructive Lung Disease (GOLD)
SPIROMETRY FOR HEALTH CARE PROVIDERS Global Initiative for Chronic Obstructive Lung Disease (GOLD) CONTENTS I. INTRODUCTION II. BACKGROUND INFORMATION A. What Is Spirometry? B. Why Perform Spirometry?
More informationCOPD PROTOCOL CELLO. Leiden
COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on
More informationPitcairn Medical Practice New Patient Questionnaire
/ / *Areas are mandatory. Failure to complete may delay the time taken to process your registration *Surname: *Forename(s): *Address: *Date of Birth/CHI: / Marital Status: Sex: Male / Female (delete as
More informationAbnormalities Consistent with Asbestos-Related Disease Among Long-Term Demolition Workers
Abnormalities Consistent with Asbestos-Related Disease Among Long-Term Demolition Workers Stephen M. Levin, M.D. Mount Sinai School of Medicine New York, New York November 1994 The Center to Protect Workers
More informationSpirometry Workshop for Primary Care Nurse Practitioners
Spirometry Workshop for Primary Care Nurse Practitioners Catherine Casey S. Jones PhD, RN, AE-C, ANP-C Certified Adult Nurse Practitioner Texas Pulmonary & Critical Care Consultants P.A. and Visiting Assistant
More information1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family
Am I an Alpha-1 Carrier? 1 ALPHA-1 FOUNDATION The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.
More information1. NAME 2. SOCIAL SECURITY NUMBER # 4. PRESENT OCCUPATION 5. PLANT 6. ADDRESS 8. TELEPHONE NUMBER 9. INTERVIEWER
ASBESTOS INITIAL MEDICAL QUESTIONNAIRE 1. NAME 2. SOCIAL SECURITY NUMBER # 3. CLOCK NUMBER 4. PRESENT OCCUPATION 5. PLANT 6. ADDRESS 7. (Zip Code) 8. TELEPHONE NUMBER 9. INTERVIEWER 10. DATE 11. Date of
More information1 ALPHA-1. What is Alpha-1? A family history... of lung disease? of liver disease? FOUNDATION
What is Alpha-1? A family history... of lung disease? of liver disease? What you need to know about Alpha-1 Antitrypsin Deficiency 1 ALPHA-1 FOUNDATION What is Alpha-1? Alpha-1 Antitrypsin Deficiency (Alpha-1)
More informationInsights for Improvement: Advancing COPD Care Through Quality Measurement. An NCQA Insights for Improvement Publication
2009 Insights for Improvement: Advancing COPD Care Through Quality Measurement An NCQA Insights for Improvement Publication Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis, emphysema,
More informationBest Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)
Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) DuPage Medical Group Case Study Organization Profile Established in 1999, DuPage Medical Group (DMG) is a multispecialty
More informationAn Overview of Asthma - Diagnosis and Treatment
An Overview of Asthma - Diagnosis and Treatment Asthma is a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness,
More informationOSHA INITIAL ASBESTOS MEDICAL QUESTIONNAIRE
OSHA INITIAL ASBESTOS MEDICAL QUESTIONNAIRE 1. NAME 2. SOCIAL SECURITY NUMBER # 3. CLOCK NUMBER FULL TIME PART TIME 4. PRESENT OCCUPATION 5. PLANT / Department 6. ADDRESS (City, ST Zip) 8. TELEPHONE NUMBER
More informationPULMONARY FUNCTION TESTS A Workshop on Simple Spirometry & Flow Volume Loops
PULMONARY FUNCTION TESTS A Workshop on Simple Spirometry & Flow Volume Loops YOU SHOULD READ THE FOLLOWING MATERIAL BEFORE Tuesday March 30 Interpretation of PFTs Learning Objectives 1. Specify the indications
More informationJames F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
More informationF r e q u e n t l y As k e d Qu e s t i o n s. Lung Disease
Lung Disease page 1 Q: What is lung disease? A: Lung disease refers to disorders that affect the lungs, the organs that allow us to breathe. Breathing problems caused by lung disease may prevent the body
More informationCOPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines f the collabative management of patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who are not adequately controlled and to define the roles and
More informationunderstanding the professional guidelines
SEVERE ASTHMA understanding the professional guidelines This guide includes information on what the European Respiratory Society (ERS) and the American Thoracic Society (ATS) have said about severe asthma.
More informationASTHMA IN INFANTS AND YOUNG CHILDREN
ASTHMA IN INFANTS AND YOUNG CHILDREN What is Asthma? Asthma is a chronic inflammatory disease of the airways. Symptoms of asthma are variable. That means that they can be mild to severe, intermittent to
More informationElectronic Health Record (EHR) Data Analysis Capabilities
Electronic Health Record (EHR) Data Analysis Capabilities January 2014 Boston Strategic Partners, Inc. 4 Wellington St. Suite 3 Boston, MA 02118 www.bostonsp.com Boston Strategic Partners is uniquely positioned
More informationCOPD. What is COPD? How many people have COPD in Canada? Who gets COPD?
What is COPD? COPD stands for Chronic Obstructive Pulmonary Disease. It is a long-term lung disease that makes it difficult for air to move into and out of the lungs. COPD is used to describe a few lung
More informationPre-Operative Services Teaching Rounds 2 Jan 2011
Pre-Operative Services Teaching Rounds 2 Jan 2011 Deborah Richman MBChB FFA(SA) Director Pre-Operative Services Department of Anesthesia Stony Brook University Medical Center, NY drichman@notes.cc.sunysb.edu
More informationEXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA
EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA A CASE STUDY EXAMINING RISK FACTORS AND COSTS OF UNCONTROLLED HYPERTENSION ISPOR 2013 WORKSHOP
More informationCOPD. Information brochure for chronic obstructive pulmonary disease.
COPD Information brochure for chronic obstructive pulmonary disease. CONTENTS What does COPD mean?...04 What are the symptoms of COPD?...06 What causes COPD?...09 Treating COPD...10 Valve therapy in COPD...12
More informationFIBROGENIC DUST EXPOSURE
FIBROGENIC DUST EXPOSURE (ASBESTOS & SILICA) WORKER S MEDICAL SCREENING GUIDELINE Prepared By Dr. T. D. Redekop Chief Occupational Medical Officer Workplace Safety & Health Division Manitoba Labour & Immigration
More informationLeanne M Poulos Patricia K Correll Brett G Toelle Helen K Reddel Guy B Marks Woolcock Institute of Medical Research, University of Sydney, NSW
Lung disease in Australia Leanne M Poulos Patricia K Correll Brett G Toelle Helen K Reddel Guy B Marks Woolcock Institute of Medical Research, University of Sydney, NSW Prepared for Lung Foundation Australia
More informationAchieving Quality and Value in Chronic Care Management
The Burden of Chronic Disease One of the greatest burdens on the US healthcare system is the rapidly growing rate of chronic disease. These statistics illustrate the scope of the problem: Nearly half of
More informationNational Learning Objectives for COPD Educators
National Learning Objectives for COPD Educators National Learning Objectives for COPD Educators The COPD Educator will be able to achieve the following objectives. Performance objectives, denoted by the
More informationMortality Assessment Technology: A New Tool for Life Insurance Underwriting
Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Guizhou Hu, MD, PhD BioSignia, Inc, Durham, North Carolina Abstract The ability to more accurately predict chronic disease morbidity
More informationEmphysema. Introduction Emphysema is a type of chronic obstructive pulmonary disease, or COPD. COPD affects about 64 million people worldwide.
Emphysema Introduction Emphysema is a type of chronic obstructive pulmonary disease, or COPD. COPD affects about 64 million people worldwide. Emphysema involves damage to the air sacs in the lungs. This
More informationCOPD is the fourth most common cause of death. Gender Bias in the Diagnosis of COPD*
Gender Bias in the Diagnosis of COPD* Kenneth R. Chapman, MD, FCCP; Donald P. Tashkin, MD, FCCP; and David J. Pye, PhD Background: COPD is thought to be more prevalent among men than women, a finding usually
More informationPharmacology of the Respiratory Tract: COPD and Steroids
Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationPublic Health Strategic Framework for COPD Prevention
Public Health Strategic Framework for COPD Prevention National Center for Chronic Disease Prevention and Health Promotion Division of Adult and Community Health Suggested Citation: Centers for Disease
More informationA Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm
A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm Zi Ye, 1 MD, Erin Austin, 1,2 PhD, Daniel J Schaid, 2 PhD, Iftikhar J. Kullo, 1 MD Affiliations: 1 Division of Cardiovascular Diseases and
More informationMedicines Use Review Supporting Information for Asthma Patients
Medicines Use Review Supporting Information for Asthma Patients What is asthma? Asthma is a chronic inflammatory disorder of the airways. The inflammation causes an associated increase in airway hyper-responsiveness,
More informationManagement of exacerbations in chronic obstructive pulmonary disease in Primary Care
Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationmedicineupdate to find out more about this medicine
medicineupdate Asking the right questions about new medicines Seretide for chronic obstructive pulmonary disease What this medicine is 1 What this medicine treats 2 Other medicines available for this condition
More informationRespiratory Concerns in Children with Down Syndrome
Respiratory Concerns in Children with Down Syndrome Paul E. Moore, M.D. Associate Professor of Pediatrics and Pharmacology Director, Pediatric Allergy, Immunology, and Pulmonary Medicine Vanderbilt University
More informationIN-HOME QUALITY IMPROVEMENT. BEST PRACTICE: DISEASE MANAGEMENT Chronic Obstructive Pulmonary Disease NURSE TRACK
IN-HOME QUALITY IMPROVEMENT BEST PRACTICE: DISEASE MANAGEMENT Chronic Obstructive Pulmonary Disease NURSE TRACK Best Practice Intervention Packages were designed for use by any In-Home Provider Agency
More information2010 QARR QUICK REFERENCE GUIDE Adults
2010 QARR QUICK REFERENCE GUIDE Adults ADULT MEASURES (19 through 64 years) GUIDELINE HEDIS COMPLIANT CPT/ICD9 CODES DOCUMENTATION TIPS Well Care Access to Ambulatory Care Ensure a preventive or other
More informationThese factors increase your chance of developing emphysema. Tell your doctor if you have any of these risk factors:
Emphysema Pronounced: em-fiss-see-mah by Debra Wood, RN En Español (Spanish Version) Definition Emphysema is a chronic obstructive disease of the lungs. The lungs contain millions of tiny air sacs called
More informationJ of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575
EFFECT OF BREATHING EXERCISES ON BIOPHYSIOLOGICAL PARAMETERS AND QUALITY OF LIFE OF PATIENTS WITH COPD AT A TERTIARY CARE CENTRE Sudin Koshy 1, Rugma Pillai S 2 HOW TO CITE THIS ARTICLE: Sudin Koshy, Rugma
More informationCOPD Intervention. Components:
COPD Intervention 1. Primary disease education Member will have an increased understanding of chronic obstructive pulmonary disease, the causes, risks and complications. Explain COPD Explain how COPD is
More informationBreathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease
Breathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease By John W. Walsh, Co-Founder and President of the COPD Foundation Breathing Easier In
More informationPathway for Diagnosing COPD
Pathway for Diagnosing Visit 1 Registry Clients at Risk Patient presents with symptoms suggestive of Exertional breathlessness Chronic cough Regular sputum production Frequent bronchitis ; wheeze Occupational
More informationPrognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
More informationBetter Breathing with COPD
Better Breathing with COPD People with Chronic Obstructive Pulmonary Disease (COPD) often benefit from learning different breathing techniques. Pursed Lip Breathing Pursed Lip Breathing (PLB) can be very
More informationGuideline on the clinical investigation of medicinal products for the treatment of asthma
22 October 2015 CHMP/EWP/2922/01 Rev.1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of medicinal products for the treatment of Draft Agreed by Respiratory
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationChanges in physical activity and all-cause mortality in COPD
ERJ Express. Published on July 25, 2014 as doi: 10.1183/09031936.00023214 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Changes in and all-cause mortality in COPD Anouk W. Vaes 1,2, Judith Garcia-Aymerich
More informationLogistics. Registration for free continuing education (CE) hours or certificate of attendance through TRAIN at: https://tx.train.
. DSHS Grand Rounds Logistics Registration for free continuing education (CE) hours or certificate of attendance through TRAIN at: https://tx.train.org Streamlined registration for individuals not requesting
More informationProf. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim
Prof. Florian Gantner Vice President Respiratory Diseases Research Boehringer Ingelheim Research and Development in Practice: COPD Chronic Obstructive Pulmonary Disease (COPD) Facts Main cause of COPD
More informationElectronic Medical Record Use and the Quality of Care in Physician Offices
Electronic Medical Record Use and the Quality of Care in Physician Offices National Conference on Health Statistics August 17, 2010 Chun-Ju (Janey) Hsiao, Ph.D, M.H.S. Jill A. Marsteller, Ph.D, M.P.P.
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationHospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care
Hospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care Charley P. Starnes, RRT, RCP Clinical Respiratory Specialist- COPD Education Important Milestones July 2011-
More informationRES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP
RES/006/APR16/AR Speaker : Dr. Pither Sandy Tulak SpP Definition of Asthma (GINA 2015) Asthma is a common and potentially serious chronic disease that imposes a substantial burden on patients, their families
More informationFACILITATOR/MENTOR GUIDE
FACILITATOR/MENTOR GUIDE Descriptive analysis variables table shells hypotheses Measures of association methods design justify analytic assess calculate analysis problem stratify confounding statistical
More informationGlobal Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease
Page 1 of 67 AJRCCM Articles in Press. Published on August 9, 2012 as doi:10.1164/rccm.201204-0596pp GOLD Executive Summary Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive
More informationAsthma Intervention. An Independent Licensee of the Blue Cross and Blue Shield Association.
Asthma Intervention 1. Primary disease education Member will have an increased understanding of asthma and the classification by severity, the risks and the complications. Define asthma Explain how lungs
More informationInhaled Corticosteroids and Diabetes Onset
Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression Journal Club October 13, 2010 By Anya Litvak, Kik Keiko Greenberg, and Jonathan Chrispin Background Inhaled corticosteroids are commonly
More informationAsthma and COPD Diagnoses and prescriptions in Swedish primary care
Asthma and COPD Diagnoses and prescriptions in Swedish primary care Paolina Weidinger Department of Primary Health Care Institute of Medicine Sahlgrenska Academy at University of Gothenburg Gothenburg
More informationProvider Newsletter March 2011
Provider Newsletter March 2011 2010 Practitioner Satisfaction Survey Results Molina Healthcare of California conducts an annual Satisfaction Survey with Primary Care Practitioners in Riverside, San Bernardino,
More informationBackground information
Background information Asthma Asthma is a complex disease affecting the lungs that can be managed but cannot be cured. 1 Asthma can be controlled well in most people most of the time, although some people
More informationUnited Lung & Sleep Clinic Asbestos Questionnaire
Date United Lung & Sleep Clinic Asbestos Questionnaire 1. Name,, Last First M.I. 2. Address 3. Home Phone: ( ) - Area Code,, City State Zip Code 4. Social Security # : - - 5. Birthdate: / / Month Day Year
More informationCoding Guidelines for Certain Respiratory Care Services July 2014
Coding Guidelines for Certain Respiratory Care Services Overview From time to time the AARC receives inquiries about respiratory-related coding and coverage issues through its Help Line or Coding Listserv.
More informationGCE AS/A level 1661/01A APPLIED SCIENCE UNIT 1. Pre-release Article for Examination in January 2010 JD*(A09-1661-01A)
GCE AS/A level 1661/01A APPLIED SCIENCE UNIT 1 Pre-release Article for Examination in January 2010 JD*(A09-1661-01A) 2 BLANK PAGE 3 Information for Teachers The attached article on asthma is based on some
More informationGeneral and Abdominal Adiposity and Risk of Death in Europe
Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke General and Abdominal Adiposity and Risk of Death in Europe Tobias Pischon Department of Epidemiology German Institute of Human Nutrition Potsdam-Rehbruecke
More informationLongitudinal Modeling of Lung Function in Respiratory Drug Development
Longitudinal Modeling of Lung Function in Respiratory Drug Development Fredrik Öhrn, PhD Senior Clinical Pharmacometrician Quantitative Clinical Pharmacology AstraZeneca R&D Mölndal, Sweden Outline A brief
More informationInformation for Behavioral Health Providers in Primary Care. Asthma
What is Asthma? Information for Behavioral Health Providers in Primary Care Asthma Asthma (AZ-ma) is a chronic (long-term) lung disease that inflames and narrows the airways. Asthma causes recurring periods
More informationPulmonary Disorders. Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD)
RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Pulmonary Disorders Chronic Obstructive Pulmonary Disease (COPD) Characterized by decreased expiratory airflow Reduction in expiratory
More informationCOPD Prescribing Guidelines
South Staffordshire Area Prescribing Group COPD Prescribing Guidelines Inhaler choices in this guideline are different from previous versions produced by the APG. It is not expected patients controlled
More informationDescription of the OECD Health Care Quality Indicators as well as indicator-specific information
Appendix 1. Description of the OECD Health Care Quality Indicators as well as indicator-specific information The numbers after the indicator name refer to the report(s) by OECD and/or THL where the data
More informationThe patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.
Emergency Room Asthma Management Algorithm The Emergency Room Asthma Management Algorithm is to be used for any patient seen in the Emergency Room with the diagnosis of asthma. (The initial history should
More informationBronchodilators in COPD
TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for
More informationYour Results. For more information visit: www.sutton.gov.uk/healthchecks. Name: Date: In partnership with
Your Results Name: Date: For more information visit: www.sutton.gov.uk/healthchecks In partnership with Introduction Everyone is at risk of developing diabetes, heart disease, kidney disease, stroke and
More informationICD-10 Rural or urban; It impacts all providers. Presented by: Joe Nichols MD (Health Data Consulting) Date: Sept 27, 2013
ICD-10 Rural or urban; It impacts all providers Presented by: Joe Nichols MD (Health Data Consulting) Date: Sept 27, 2013 Agenda ICD-10, how will it impact my business? What is the role of the physician
More informationNHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia. Produced by: National Cardiovascular Intelligence Network (NCVIN)
NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia Produced by: National Cardiovascular Intelligence Network (NCVIN) Date: August 2015 About Public Health England Public Health England
More informationClassifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age
Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Components of Severity Symptoms Intermittent 2 days/week Classification of Asthma Severity (0 4 years of age) Persistent
More informationBreathe With Ease. Asthma Disease Management Program
Breathe With Ease Asthma Disease Management Program MOLINA Breathe With Ease Pediatric and Adult Asthma Disease Management Program Background According to the National Asthma Education and Prevention Program
More informationBiostatistics: Types of Data Analysis
Biostatistics: Types of Data Analysis Theresa A Scott, MS Vanderbilt University Department of Biostatistics theresa.scott@vanderbilt.edu http://biostat.mc.vanderbilt.edu/theresascott Theresa A Scott, MS
More informationSmoking Cessation Program
Smoking Cessation Program UHN Information for people who are ready to quit smoking Read this information to learn: why you should quit smoking how the Smoking Cessation Program works treatments to help
More information